Right now, T-cell therapy is being developed for brain tumors, sarcoma (a type of cancer that develops from certain tissues, like bone or muscle), prostate cancer, and lung cancer.
Moreover that part of the brain is not yet developed for specific tasks and may be developed for other uses than were originally intended [ 24].
Outcome often is evaluated on a good-bad dichotomous scale that was developed for traumatic brain injury 40 years ago.
A similar approach has been developed for human brain tumors with the establishment of several glioma neural stem cell lines stably enriched in CSCs.
Recently, T1 measurements combined with modelling methods have been developed for estimating brain blood volume and permeability based on first-pass kinetics (Hacklander et al, 1996, 1997; Ludemann et al, 2001; Johnson et al, 2004).
Moreover, a plethora of neuroprotective strategies have been developed for ameliorating brain damage and preserving or restoring neurological function in animal models of stroke, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and other neurological disorders [ 3– 5].
Sophisticated image analysis methods have been developed for the human brain, but such tools still need to be adapted and optimized for quantitative small animal imaging.
Therefore, targeted molecular based therapies are developed for treatment of brain tumors that could deliver the antitumor drugs to the target sites and stop aberrant signaling pathways in the brain.
